Literature DB >> 12819031

C-reactive protein activates complement in infarcted human myocardium.

Remco Nijmeijer1, Wim K Lagrand, Yvonne T P Lubbers, Cees A Visser, Chris J L M Meijer, Hans W M Niessen, C Erik Hack.   

Abstract

Circulating levels of C-reactive protein (CRP) constitute a cardiovascular risk marker. Immunohistochemical studies have revealed co-localization of CRP and activated complement in human infarcted myocardium suggesting CRP to enhance inflammation in ischemic myocardium by inducing local complement activation. The aim was to establish whether CRP activates complement in infarcted human myocardium and to assess the relationship between this activation and the duration of infarction. Myocardial tissue samples from 56 patients that had died from acute myocardial infarction were evaluated. Specimens were taken from infarcted as well as noninfarcted sites of the heart. CRP-mediated complement activation was assessed by immunohistochemistry and by measuring levels of complement, CRP, and CRP-complement complexes, specific markers for CRP-mediated activation, in homogenates of the heart. Infarctions of 12 hours to 5 days had significantly more extensive depositions of complement and CRP and contained significantly more CRP, activated complement, and CRP-complement complexes than infarctions that were less than 12 hours old. Levels of CRP complexes correlated significantly with CRP and complement concentrations in the infarctions, as well as with the extent of complement and CRP depositions as measured via immunohistochemistry. Specific activation products of CRP-mediated activation of complement are increased in infarcts of more than 12 hours in duration and correlate with the extent of complement depositions. Hence, CRP seems to enhance local inflammatory reactions ensuing in human myocardial infarcts of more than 12 hours duration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819031      PMCID: PMC1868178          DOI: 10.1016/S0002-9440(10)63650-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits.

Authors:  I KUSHNER; L RAKITA; M H KAPLAN
Journal:  J Clin Invest       Date:  1963-02       Impact factor: 14.808

2.  Activation of the complement system by recombinant tissue plasminogen activator.

Authors:  W R Bennett; D H Yawn; P J Migliore; J B Young; C M Pratt; A E Raizner; R Roberts; R Bolli
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

3.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

4.  Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q.

Authors:  J E Volanakis; M H Kaplan
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

5.  Independent prognostic value of elevated C-reactive protein in unstable angina.

Authors:  E R Ferreirós; C P Boissonnet; R Pizarro; P F Merletti; G Corrado; A Cagide; O O Bazzino
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion.

Authors:  F Tomai; F Crea; A Gaspardone; F Versaci; A S Ghini; L Chiariello; P A Gioffrè
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

7.  Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction.

Authors:  H Tomoda; N Aoki
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

8.  Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium.

Authors:  H W Niessen; W K Lagrand; H J Rensink; C J Meijer; L Aarden; C E Hack; C Visser
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

9.  Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion.

Authors:  P R Maroko; C B Carpenter; M Chiariello; M C Fishbein; P Radvany; J D Knostman; S L Hale
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

10.  Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.

Authors:  C de Zwaan; A H Kleine; J H C Diris; J F C Glatz; H J J Wellens; P F W Strengers; M Tissing; C E Hack; M P van Dieijen-Visser; W T Hermens
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

View more
  18 in total

1.  C-reactive protein in vulnerable coronary plaques.

Authors:  Silja Norja; Lauri Nuutila; Pekka J Karhunen; Sirkka Goebeler
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  IgM colocalises with complement and C reactive protein in infarcted human myocardium.

Authors:  P A J Krijnen; C Ciurana; T Cramer; T Hazes; C J L M Meijer; C A Visser; H W M Niessen; C E Hack
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

Review 3.  Molecular tissue changes in early myocardial ischemia: from pathophysiology to the identification of new diagnostic markers.

Authors:  Aleksandra Aljakna; Tony Fracasso; Sara Sabatasso
Journal:  Int J Legal Med       Date:  2018-01-23       Impact factor: 2.686

4.  Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice.

Authors:  Q Guo; J Cheng; J Zhang; B Su; C Bian; S Lin; C Zhong
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

Review 5.  Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors.

Authors:  Terry W Du Clos; Carolyn Mold
Journal:  Curr Opin Organ Transplant       Date:  2011-02       Impact factor: 2.640

6.  Systemic complement activation following human acute ischaemic stroke.

Authors:  E D Pedersen; U Waje-Andreassen; C A Vedeler; G Aamodt; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

7.  Systemic inflammation in nonischemic dilated cardiomyopathy.

Authors:  Luisa De Gennaro; Natale Daniele Brunetti; Andrea Cuculo; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  Heart Vessels       Date:  2008-11-27       Impact factor: 2.037

8.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

9.  C4b-binding protein is present in affected areas of myocardial infarction during the acute inflammatory phase and covers a larger area than C3.

Authors:  Leendert A Trouw; Marcin Okroj; Koba Kupreishvili; Göran Landberg; Bengt Johansson; Hans W M Niessen; Anna M Blom
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

Review 10.  Pentraxins: structure, function, and role in inflammation.

Authors:  Terry W Du Clos
Journal:  ISRN Inflamm       Date:  2013-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.